Nisa Investment Advisors’s Protagonist Therapeutics PTGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$514K Buy
4,191
+389
+10% +$40.6K ﹤0.01% 968
2026
Q1
$401K Buy
3,802
+22
+0.6% +$1.95K ﹤0.01% 1027
2025
Q4
$330K Sell
3,780
-205
-5% -$16.8K ﹤0.01% 1113
2025
Q3
$265K Buy
3,985
+82
+2% +$4.66K ﹤0.01% 1182
2025
Q2
$216K Buy
3,903
+1,071
+38% +$51.4K ﹤0.01% 1199
2025
Q1
$137K Sell
2,832
-301
-10% -$12.6K ﹤0.01% 1321
2024
Q4
$121K Buy
3,133
+295
+10% +$12.9K ﹤0.01% 1422
2024
Q3
$128K Buy
2,838
+93
+3% +$3.76K ﹤0.01% 1378
2024
Q2
$95.1K Buy
2,745
+54
+2% +$1.58K ﹤0.01% 1491
2024
Q1
$77.9K Buy
2,691
+52
+2% +$1.42K ﹤0.01% 1548
2023
Q4
$60.5K Hold
2,639
– – ﹤0.01% 1593
2023
Q3
$44K Hold
2,639
– – ﹤0.01% 1761
2023
Q2
$72.9K Buy
2,639
+590
+29% +$14.8K ﹤0.01% 1616
2023
Q1
$47K Hold
2,049
– – ﹤0.01% 1735
2022
Q4
$22K Buy
2,049
+49
+2% +$413 ﹤0.01% 2037
2022
Q3
$16K Hold
2,000
– – ﹤0.01% 2101
2022
Q2
$16K Sell
2,000
-24,390
-92% -$295K ﹤0.01% 2100
2022
Q1
$625K Sell
26,390
-760
-3% -$21.4K ﹤0.01% 1008
2021
Q4
$795K Buy
27,150
+26,700
+5,933% +$844K 0.01% 894
2021
Q3
$8K Hold
450
– – ﹤0.01% 2230
2021
Q2
$20K Hold
450
– – ﹤0.01% 2138
2021
Q1
$12K Hold
450
– – ﹤0.01% 2189
2020
Q4
$9K Buy
+450
New +$9.69K ﹤0.01% 2220

Other funds holding PTGX

Nisa Investment Advisors's PTGX Position: Q2 2026 in Review

Nisa Investment Advisors increased its Protagonist Therapeutics (PTGX) stake by 10% in Q2 2026, buying an estimated $40.6K and bringing the position to 4,191 shares worth $514K. The position accounts for ﹤0.01% of the portfolio, ranked #968.

Nisa Investment Advisors first reported a position in PTGX in Q4 2020 and has held it in 23 quarters since. The position peaked at $795K in Q4 2021. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Nisa Investment Advisors held 4,191 shares of Protagonist Therapeutics worth $514K as of Q2 2026.
  • Nisa Investment Advisors bought 389 Protagonist Therapeutics shares in Q2 2026, an estimated $40.6K.
  • Protagonist Therapeutics made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q2 2026, its #968 holding.
  • Nisa Investment Advisors first reported a position in Protagonist Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • Nisa Investment Advisors's Protagonist Therapeutics position peaked at $795K in Q4 2021.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Nisa Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.